Along this line, it would also be of interest to investigate the impact of RBM3 as a predictor of response to platinum-based chemotherapy, both in the neoadjuvant, adjuvant and palliative setting, cisplatin being one of the cornerstones in the medical treatment of bladder cancer [17-20]. Here, RBM3 is linked to urinary bladder cancer.